Advantage Trust Company’s CVS Health CVS Stock Holding History

Advantage Trust Company’s Portfolio CVS Stock Details CVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-550	Closed	-$43.4K	–	174
2023 Q4	$43.4K	Buy	+550	New	+$39.1K	0.03%	121

Other funds holding CVS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Advantage Trust Company's CVS Position: Q1 2024 in Review

Advantage Trust Company sold out of CVS Health (CVS) in Q1 2024, closing a stake of 550 shares — an estimated $43.4K sold.

Advantage Trust Company first reported a position in CVS in Q4 2023 and held it in 1 quarter. The position peaked at $43.4K in Q4 2023. 2,177 funds tracked by Wall St. Rank hold CVS as of Q1 2024.

Advantage Trust Company reported no remaining CVS Health position as of Q1 2024 after selling out during the quarter.
Advantage Trust Company sold 550 CVS Health shares in Q1 2024, an estimated $43.4K.
Advantage Trust Company first reported a position in CVS Health in Q4 2023 and held it in 1 quarter.
Advantage Trust Company's CVS Health position peaked at $43.4K in Q4 2023.
2,177 funds tracked by Wall St. Rank held CVS Health as of Q1 2024.

Based on Advantage Trust Company's 13F filing for Q1 2024, filed 7 May 2024.